Cetuximab in combination with irinotecan-5-fluorouracil-folinic acid FOLFIRI in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I-II studyReport as inadecuate




Cetuximab in combination with irinotecan-5-fluorouracil-folinic acid FOLFIRI in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I-II study - Download this document for free, or read online. Document in PDF available to download.

(2009)BMC CANCER.9. Mark abstract Background: This study was designed to investigate the efficacy and safety of the epidermal growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable metastatic colorectal cancer. Methods: The 5-FU dose was selected on the basis of dose-limiting toxicities (DLTs) during part I of the study. Patients received cetuximab (400 mg/m(2) initial dose and 250 mg/m(2)/week thereafter) and every 2 weeks irinotecan (180 mg/m(2)), FA (400 mg/m(2)) and 5-FU (either low dose [LD], 300 mg/m(2) bolus plus 2,000 mg/m(2) 46-hour infusion, n = 7; or, high-dose [HD], 400 mg/m(2) bolus plus 2,400 mg/m(2); n = 45). Results: Only two DLTs occurred in the HD group, and HD 5-FU was selected for use in part II. Apart from rash, commonly observed grade 3/4 adverse events such as leucopenia, diarrhoea, vomiting and asthenia occurred within the expected range for FOLFIRI. Among 52 patients, the overall response rate was 48%. Median progression-free survival (PFS) was 8.6 months (counting all reported progressions) and the median overall survival was 22.4 months. Treatment facilitated the resection of initially unresectable metastases in fourteen patients (27%): of these, 10 patients (71%) had no residual tumour after surgery, and these resections hindered the estimation of PFS. Conclusion: The combination of cetuximab and FOLFIRI was active and well tolerated in this setting. Initially unresectable metastases became resectable in one-quarter of patients, with a high number of complete resections, and these promising results formed the basis for the investigation of FOLFIRI with and without cetuximab in the phase III CRYSTAL trial.

Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-687062



Author: Jean-Luc Raoul, Jean-Luc Van Laethem, Marc Peeters , Catherine Brezault, Fares Husseini, Laurent Cals, Johannes Nippgen, Anja-Hele

Source: https://biblio.ugent.be/publication/687062



DOWNLOAD PDF




Related documents